FDA Approves Klisyri for Broadened Actinic Keratosis Treatment Area on Face or Scalp

Monday, 10 June 2024, 03:16

FDA has approved Almirall's Klisyri for treating Actinic Keratosis on a larger area of the face or scalp, covering up to 100 cm². This expanded approval provides a new option for individuals dealing with this skin condition that could lead to skin cancer. Klisyri offers a promising solution for managing Actinic Keratosis effectively, enhancing treatment accessibility for patients.

https://store.livarava.com/0abbf2e3-26f2-11ef-a412-9d5fa15a64d8.jpg — FDA Approves Klisyri for Broadened Actinic Keratosis Treatment Area on Face or Scalp

FDA Approves Klisyri for Actinic Keratosis Treatment

FDA has granted approval to Almirall's Klisyri for effectively treating Actinic Keratosis.

Enhanced Treatment Area

Expanded treatment area for face or scalp up to 100 cm²

Klisyri offers a promising solution for managing Actinic Keratosis effectively, enhancing treatment accessibility for patients.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.